Steve Martin New CTO at Beyond Genomics, David Howson Joins Accelr8 as President, David Smoller Goes to Sigma-Aldrich as VP R&D, Craig Mello Advisor at Invitrogen, Alfred Knudson Wins Kyoto Prize, and Others

Stephen Martin, after leaving Applied Biosystems, has resurfaced at Beyond Genomics, where he has become senior vice president and chief technical officer, the company said yesterday. Prior to joining Beyond Genomics, he was the senior director of the Discovery Proteomics and Small Molecule Research Center at ABI. Martin holds a PhD in analytical chemistry from MIT and a BA in chemistry from Boston University.

David Howson has become president of Accelr8, the company said last month. He has been a consultant for companies including Pfizer, Boston Scientific, and Becton Dickinson. Howson, who used to be a consultant to Accelr8, started his new appointment on April 1.

David Smoller has become vice president for research and development at Sigma-Aldrich, the company said last week. He joins Sigma-Aldrich from St. Louis-based ProteoPlex, where he was CEO and president. Prior to that, he founded Genome Systems, which was acquired by Incyte in 1996. Smoller holds a PhD in molecular biology and a bachelor's degree in biology from Emory University.

Gregory Landes has joined Lexicon Genetics as vice president of biotherapeutics, the company, based in The Woodlands, Texas, said yesterday. In the past, he was vice president of product discovery at Abgenix and vice president of genetics and genomics at Genzyme. Landes holds a PhD in biochemistry and a BA in chemistry from the University of Kansas.

Craig Mello has become a scientific advisor for Invitrogen in the area of RNAi research, the company said yesterday. He is a professor at the University of Massachusetts medical school and a Howard Hughes investigator. Mello holds a PhD from Harvard University and a bachelor's degree in biochemistry from Brown University.

Alfred Knudson Jr. has won the 2004 Kyoto Prize of the Inamori Foundation, the Fox Chase Cancer Center said last week. He is a cancer researcher at the Philadelphia-based center. The award recognizes Knudson's role in establishing the theory of tumor suppressor genes, known as the "two-hit" theory. Along with the prize, which will be awarded at a ceremony in Kyoto on November 10, he will receive about $450,000. Knudson holds a PhD and a BS from Caltech, and an MD from Columbia University.

Mary-Claire King has won the 2004 Genetics Prize of the Peter Gruber Foundation, the foundation said yesterday. King, who located the BRCA1 breast cancer gene, is a professor at the University of Washington school of medicine. She holds a PhD in genetics from the University of California Berkeley and a BA in mathematics from Carleton College in Minnesota. King will receive the prize, which comes with $200,000, at the American Society of Human Genetics meeting in Toronto, Canada, on October 27.

William Castell has become vice chairman of the board of directors of General Electric, the company said last week. Castell will remain in Chalfont St. Giles, UK. He became president and CEO of GE Healthcare in April, following GE's acquisition of Amersham, which he joined as CEO in 1989. Castell is also an executive officer and a member of the corporate executive office of GE. He holds a BA in business studies from the City of London College.

Gordon Binder has joined the board of directors of Cellular Genomics, the Branford, Conn.-based company said on Monday. He assumed his post after the company completed a Series C financing round this week. Binder is a founder and managing director of Coastview Capital. Prior to that, he was CEO of Amgen. Binder received an MBA from Harvard Business School and a bachelor's degree in electrical engineering from Purdue University.

Robert Rosenthal has been elected to the board of directors of ESA, the Chelmsford, Mass.-based biomedical instrument and reagent company said last week. He is president and CEO of TekCel. Previously, he was president of PerkinElmer's instruments division. Rosenthal holds a PhD in physical chemistry from Emory University, an MS in chemistry form State University of New York Buffalo, and a BS in chemistry from the University of Maryland.

Melvin Booth has joined the board of directors of Millipore, the Billerica, Mass.-based company said last week. Until his retirement in January, he was president and COO of MedImmune. Prior to that, he was president and COO of Human Genome Sciences. Booth holds a doctor of science degree from Northwest Missouri State University.

Stanley Appel has become chairman of the scientific advisory board of Power3 Medical Products, the proteomics company, located in The Woodlands, Texas, said yesterday. He is chairman of the department of neurology at Baylor College of Medicine.